Lodgement of Information Memorandum With ASIC

  As announced on 1 September 2009, Unilife
Medical Solutions Limited (ASX: UNI) (PINKSHEETS: UNIFF) (Unilife
Australia) entered into a Merger Implementation Agreement with Unilife
Corporation (Unilife USA) to facilitate the proposed redomiciliation of the
Unilife group in the United States of America (Proposed Transaction).

The Directors of Unilife Australia are pleased to confirm that the next stage of the process for the redomiciliation has now been completed by way of the lodgement of an Information Memorandum with respect to the Proposed Transaction with the Australian Securities and Investments Commission (ASIC) for review. The Information Memorandum comprises:

--  the explanatory statement in relation to the schemes of arrangement;
--  the Notice of Meeting to consider and approve the share scheme of
    arrangement;
--  the Notice of Meeting to consider and approve the option scheme of
    arrangement; and
--  the Information Memorandum with respect to the listing of Unilife
    USA on the Australian Securities Exchange.
    

The Information Memorandum is a substantial legal document covering key matters relating to the Unilife group, the Proposed Transaction, the listing of Unilife Corporation on ASX and shareholders and optionholders' entitlement to vote at the Scheme Meetings to be held in January 2010. Following ASIC review and Court approval, the Information Memorandum, a Notice of Meeting for an Extraordinary General Meeting to be held on the same day as the Scheme Meetings and relevant proxy forms will be mailed to all shareholders and optionholders for their consideration.

About Unilife

Unilife Medical Solutions Ltd is an ISO 13485 certified company that designs, develops and supplies innovative safety medical devices. Listed on the Australian Securities Exchange (ASX: UNI) since 2002, Unilife has FDA-registered manufacturing facilities in the US State of Pennsylvania and a proprietary portfolio of clinical and prefilled safety syringes designed for use within healthcare and pharmaceutical markets.

Shareholder / Analyst Enquiries: Australia Jeff Carter Phone: + 61 2 8346 6500 United States Stuart Fine Phone: + 1 908 469 1788